A smarter way to screen for breast cancer is emerging

The landscape of breast cancer screening is on the cusp of a transformative shift, moving away from a ‘one-size-fits-all’ age-based approach toward a nuanced, individualized strategy. Groundbreaking research from the WISDOM study, involving 46,000 women across the United States, indicates that personalizing screening frequency based on comprehensive risk assessment not only maintains but potentially enhances detection efficacy, reducing the incidence of advanced cancers without over-screening low-risk individuals. These pivotal findings, coordinated by UCSF, were published on December 12 in the prestigious journal JAMA and simultaneously presented at the San Antonio Breast Cancer Symposium, marking a significant milestone in breast cancer prevention and early detection.

Re-evaluating Traditional Screening Paradigms

For decades, breast cancer screening guidelines have largely been predicated on age, often recommending routine mammograms for women starting at 40 or 50, irrespective of their diverse risk profiles. This standardized approach, while instrumental in reducing breast cancer mortality, has faced increasing scrutiny. Critics point to its inherent limitations: it may lead to overdiagnosis and overtreatment in low-risk individuals, exposing them to unnecessary anxiety, biopsies, and radiation, while simultaneously failing to adequately screen high-risk women who might develop aggressive cancers at younger ages or require more frequent surveillance.

Breast cancer remains a formidable public health challenge. It is the most commonly diagnosed cancer among women in the United States, excluding skin cancers, affecting approximately 1 in 8 women over their lifetime. In 2023 alone, an estimated 297,790 new cases of invasive breast cancer and 55,720 cases of non-invasive (in situ) breast cancer were projected, with over 43,000 women succumbing to the disease. The sheer prevalence underscores the critical need for optimal screening strategies that balance early detection with minimizing harm. The traditional guidelines, often debated among organizations like the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) regarding the optimal age to start and frequency of screening, have primarily focused on identifying cancers at an early, treatable stage. However, they have struggled to address the inherent heterogeneity of breast cancer risk.

The Genesis and Design of the WISDOM Study

The WISDOM (Women Informed to Screen Depending On Measures of Risk) study was conceived to directly challenge and evaluate the efficacy of this conventional age-based screening. Launched in 2016, the study embarked on an ambitious mission: to compare the outcomes of traditional annual mammography against a dynamic, individualized screening strategy rooted in a woman’s unique risk factors. The foundational premise was simple yet profound: if risk varies greatly, should not screening vary accordingly?

Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author, articulated the vision: "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice. The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her statement highlights a departure from simplistic age cut-offs to a holistic evaluation of an individual’s susceptibility.

The study employed well-validated risk models to categorize participants into four distinct risk groups. This comprehensive assessment integrated a multitude of factors, moving far beyond mere chronological age. These factors included:

• Age: While not the sole determinant, age remained a component in the overall risk calculation.
• Genetic Information: This included testing for known pathogenic variants like BRCA1 and BRCA2, as well as evaluating polygenic risk scores.
• Lifestyle Factors: Elements such as diet, physical activity levels, alcohol consumption, and reproductive history (e.g., age at first menstruation, parity, breastfeeding history).
• Health History: Personal and family history of breast cancer, prior benign breast biopsies, and exposure to certain medications.
• Breast Density: A significant independent risk factor, often identified through mammography, where dense breast tissue can obscure tumors.

By synthesizing these diverse data points, researchers aimed to create a more accurate and predictive risk profile for each woman, thereby optimizing her screening regimen.

Key Findings: A Blueprint for Personalized Screening

The WISDOM study’s results offer compelling evidence for the superiority of a risk-based approach. The 46,000 participants were dynamically assigned screening frequencies based on their calculated risk:

• Lowest Risk Group (26% of participants): Women in this cohort were advised to delay screening until age 50 or until their algorithmic risk profile reached that of a typical 50-year-old woman. This recommendation challenges the long-held belief that all women must begin screening in their 40s, suggesting that for a significant portion of the population, earlier screening may not offer proportional benefits and could lead to unnecessary procedures.
• Average Risk Group (62% of participants): This largest group was advised to undergo screening every two years. This aligns with recommendations from some major health organizations like the USPSTF, providing further validation for biennial screening in a broad segment of the population.
• Elevated Risk Group (8% of participants): For these women, annual mammograms were recommended. This increased frequency ensures closer surveillance for those with a moderately higher likelihood of developing breast cancer, enabling earlier detection.
• Highest Risk Group (2% of participants): This critically important group received the most intensive screening protocol, advised to receive screening twice a year, alternating between mammography and MRI, regardless of age. This aggressive strategy is designed to catch rapidly growing or aggressive tumors in individuals with substantial genetic or familial predispositions, where early detection can be life-saving.

Crucially, the study found that this personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This finding directly refutes concerns that less frequent screening for lower-risk women might result in missed cancers or delayed detection. Instead, it demonstrates that resources can be reallocated more effectively, intensifying screening for those who need it most, without compromising outcomes for others.

Patient acceptance of this novel approach was also remarkably high. Among women who chose not to be randomized into the study arms but instead joined an observational group and selected their preferred screening strategy, a resounding 89% opted for risk-based screening. This strong preference suggests a public readiness to embrace more tailored healthcare models, recognizing the potential benefits of an approach that considers their individual circumstances.

Jeffrey A. Tice, MD, a UCSF professor of Medicine and co-author specializing in breast cancer risk assessment tools, emphasized the efficiency of this strategy: "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer." This efficiency translates not only to improved health outcomes but also to potential healthcare cost savings by optimizing the utilization of expensive screening modalities like mammography and MRI.

Personalized Prevention for Higher-Risk Women

Beyond tailored screening schedules, the WISDOM study also incorporated personalized prevention strategies for women identified as having elevated or highest risk. This proactive approach underscores a holistic view of health, extending beyond mere detection to active risk reduction.

Participants in these higher-risk categories received customized guidance designed to lower their chances of developing breast cancer. This support included:

• Access to an online decision-making tool: This digital resource provided personalized information and helped women understand their risk factors and potential preventive measures, empowering them to make informed choices.
• Direct contact with a breast health specialist: This personalized consultation offered expert advice, addressing individual concerns and tailoring recommendations to specific needs.
• Lifestyle changes: Recommendations covered evidence-based interventions such as improving diet (e.g., adopting a Mediterranean-style diet rich in fruits, vegetables, and whole grains), increasing physical activity (e.g., regular moderate-to-vigorous exercise), and maintaining a healthy weight. These factors are well-established modifiers of breast cancer risk.
• Discussions about risk-reducing medications: For some women, medications like tamoxifen or raloxifene, which can significantly reduce the risk of estrogen receptor-positive breast cancer, were discussed as potential preventive options. These discussions were carefully weighed against potential side effects and individual patient profiles.

This integrated approach to prevention and screening represents a paradigm shift, moving towards a truly comprehensive breast health management plan.

Expanding the Horizon of Genetic Testing

One of the most profound and potentially practice-altering findings of the WISDOM study pertains to genetic testing. Current clinical guidelines for genetic testing often rely heavily on family history, typically recommending testing only for individuals with multiple affected relatives or early-onset cancers in their lineage. The WISDOM study challenged this criterion by offering genetic testing to all participants, regardless of their family history.

The results were striking: 30% of women who tested positive for a genetic variant linked to a higher breast cancer risk reported no family history of the disease. This is a critical revelation, implying that a substantial proportion of women at elevated genetic risk are currently being missed by conventional screening protocols that rely solely on family history. For these women, earlier and more intensive screening, potentially including MRI, could be life-saving. Identifying these individuals opens a new avenue for targeted prevention and surveillance that was previously inaccessible.

Beyond well-known pathogenic variants like BRCA1 and BRCA2, the study also explored the utility of smaller DNA changes, which can be combined to form a polygenic risk score (PRS). A PRS aggregates the effects of numerous common genetic variants, each having a small individual impact but collectively contributing to overall risk. This sophisticated approach significantly improved the precision of risk predictions. As a result, 12% to 14% of participants were reassigned to a different risk category based on their PRS, demonstrating the added value of this advanced genetic profiling in refining individual risk assessment.

Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study, emphasized the broader implications: "This is one of the first studies to offer genetic testing to all women, regardless of family history. When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." This highlights the potential for universal genetic screening to become a standard component of breast cancer risk assessment in the future, dramatically enhancing early detection and personalized prevention efforts.

Broader Implications and Future Directions

The findings of the WISDOM study are poised to catalyze significant changes in clinical guidelines and public health recommendations for breast cancer screening globally. Major organizations like the American Cancer Society and the U.S. Preventive Services Task Force will undoubtedly review this evidence as they periodically update their recommendations. The shift from rigid age-based rules to dynamic, risk-stratified approaches could lead to:

• Improved Patient Outcomes: By allocating more intensive screening to high-risk individuals, aggressive cancers can be detected earlier, leading to better prognosis and survival rates. Conversely, reducing unnecessary screening for low-risk women mitigates the harms of overdiagnosis, false positives, and anxiety.
• Enhanced Resource Allocation: Optimizing screening frequency based on risk can lead to more efficient use of healthcare resources, potentially reducing overall costs associated with breast cancer screening and follow-up procedures.
• Empowered Patients: A personalized approach empowers women with more detailed information about their individual risk, allowing for shared decision-making with their healthcare providers about the most appropriate screening and prevention strategies.
• Equity in Screening: While not explicitly detailed, a risk-based approach, especially one incorporating genetic testing, could help identify disparities in risk factors and ensure that women from diverse backgrounds receive appropriate screening, potentially addressing existing inequities in cancer care.

However, implementing such a personalized system will not be without its challenges. It requires widespread access to comprehensive risk assessment tools, including genetic testing and breast density evaluation. Healthcare providers will need extensive training in interpreting these complex risk profiles and communicating personalized recommendations to patients. Furthermore, the psychological impact of knowing one’s individual risk, particularly for those identified as high-risk, will need careful management and support systems.

Recognizing the evolving nature of risk assessment, researchers are continuing to refine their methodologies through the WISDOM 2.0 study, which is actively enrolling participants. The primary goal of this follow-up study is to further enhance the identification of women at higher likelihood of developing aggressive breast cancers and to develop even more precise screening and prevention strategies tailored to their long-term health needs. This iterative process of research and refinement ensures that the science of personalized breast cancer screening remains at the forefront of medical innovation.

The WISDOM study represents a monumental leap forward in the quest for more effective and safer breast cancer screening. By championing a personalized approach rooted in comprehensive risk assessment, it promises to reshape how millions of women engage with breast health, offering a future where screening is not just routine, but truly responsive to individual needs.

Collaborating Institutions and Funding Support

This extensive research endeavor was a collaborative effort involving numerous institutions and investigators across the United States and internationally. Key contributors from UCSF included Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.

Additional investigators were affiliated with UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.

The study received substantial financial support from several key organizations, including the Patient Centered Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation. Further funding sources are detailed within the published paper.

Conflicts of interest were disclosed by the authors, with Esserman noting her role as a medical advisory panel member for Blue Cross Blue Shield and receipt of author fees from the UpToDate electronic medical information resource. Disclosures for other investigators are also available in the full research publication.